chikungunya vaccine
EU Lifts Restriction on Valneva’s Chikungunya Vaccine for Older Adults, Recommends Caution
Valneva; Chikungunya vaccine; IXCHIQ; European Medicines Agency; older adults; safety concerns; label extension; adverse events
Bavarian Nordic Sells FDA Priority Review Voucher for $160M Amid Rising Industry Prices and Program Scrutiny
Bavarian Nordic; Priority Review Voucher; FDA; voucher sale; $160 million; chikungunya vaccine; VIMKUNYA; NIH; antitrust review; biotech finance
Bavarian Nordic’s Vimkunya Approved by FDA as First Chikungunya Vaccine for Ages 12 and Up
Vimkunya, chikungunya vaccine, Bavarian Nordic, FDA approval, virus-like particle vaccine, adolescents, travelers